Sign Up Today and Learn More About Scorpion Therapeutics Stock
Invest in or calculate the value of your shares in Scorpion Therapeutics or other pre-IPO companies through EquityZen's platform.
Scorpion Therapeutics Stock (SCRT)
Scorpion Therapeutics is a precision oncology company that broadens the reach and impact of precision medicine for cancer patients.
About Scorpion Therapeutics Stock
Founded
2020
Headquarters
Boston, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.
Scorpion Therapeutics Press Mentions
Stay in the know about the latest news on Scorpion Therapeutics
Pierre Fabre Laboratories and Scorpion Therapeutics Annou...
pharmiweb • Oct 10, 2024
Most-Active US Investors In July: Andreessen Horowitz Led Cool Month
news • Aug 12, 2024
Scorpion Therapeutics Inks $150 Million Series C
vcnewsdaily • Aug 05, 2024
Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline
pulse2 • Aug 02, 2024
Boston Therapeutics rakes in $150m Series C
venturecapitaljournal • Aug 02, 2024
Scorpion Therapeutics Management
Leadership team at Scorpion Therapeutics
Founder
Gaddy Getz
Interim Chief Executive Officer
Adam Friedman
Join now and verify your accreditation status to gain access to:
- Scorpion Therapeutics current valuation
- Scorpion Therapeutics stock price
- Available deals in Scorpion Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Scorpion Therapeutics Stock
How to invest in Scorpion Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Scorpion Therapeutics through EquityZen funds. These investments are made available by existing Scorpion Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Scorpion Therapeutics stock?
Shareholders can sell their Scorpion Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
